Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $462M | $673M | $1.47B | $1.10B | $1.26B | $1.37B | $1.92B |
| Revenue growth | — | 45.6% | 118.8% | -25.5% | 15.0% | 8.8% | 40.3% |
| Gross profit | — | — | -$79.2M | $22.7M | $257M | — | — |
| Gross margin | — | — | -5.4% | 2.1% | 20.4% | — | — |
| Operating income | -$183M | -$92.7M | -$637M | -$287M | -$205M | -$45.7M | -$85.5M |
| Operating margin | -39.6% | -13.8% | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% |
| Net income | -$364M | -$136M | -$588M | -$340M | -$213M | -$43.0M | -$85.5M |
| Net margin | -78.7% | -20.3% | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% |
| EPS (diluted) | -$4.14 | -$1.54 | -$1.42 | -$0.71 | -$0.44 | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$160M | -$118M | -$282M | -$204M | -$145M | $34.8M | -$66.9M |
| Capital expenditures | $23.0K | $693K | $723K | $4.47M | $584K | $1.56M | $2.04M |
| Free cash flow | -$160M | -$119M | -$283M | -$208M | -$145M | $33.3M | -$69.0M |
| Share buybacks | $0.00 | $0.00 | $147K | $0.00 | $0.00 | $1.77M | $18.3M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $0.00 | $92.3M | $300M | $104M | $123M | $195M | $78.3M |
| Total assets | $100K | $267M | $951M | $809M | $571M | $581M | $541M |
| Total liabilities | $118K | $433M | $411M | $452M | $284M | $240M | $232M |
| Long-term debt | — | $106M | $19.9M | $0.00 | — | — | — |
| Shareholders' equity | -$489M | -$613M | $540M | $357M | $286M | $341M | $309M |
| Retained earnings | -$17.6K | -$1.03B | -$1.62B | $1.62B | -$2.16B | -$2.20B | -$2.29B |
| Shares (wtd avg diluted) | 87.8M | 88.7M | 413M | 476M | 482M | 490M | 512M |
Every figure is extracted from CLOVER HEALTH INVESTMENTS, CORP. /DE’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.